Article

Thomas Stinchcombe Discusses Immunotherapy Breakthroughs for Lung Cancer

Immunotherapies have strong potential as a treatment option for patients with NSCLC, as clinical trials have shown dramatic and durable results.

Thomas Stinchcombe, co-director of the multidisciplinary thoracic oncology program at the University of North Carolina at Chapel Hill, shares the potential of immunotherapies in non-small cell lung cancer (NSCLC).

Stinchcombe says immunotherapies have strong potential as a treatment option for patients with NSCLC, as clinical trials have shown dramatic and durable results.

Immunotherapies will hopefully become a new option for patients with NSCLC in the near future, Stinchcombe predicts, adding there is a higher tolerance in terms of side effects.

Because EGFR and ALK mutations are often found in a smaller group of patients, immunotherapies can possibly apply to a broader spectrum of patients.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.